1. Home
  2. PHVS vs GHLD Comparison

PHVS vs GHLD Comparison

Compare PHVS & GHLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • GHLD
  • Stock Information
  • Founded
  • PHVS 2015
  • GHLD 1960
  • Country
  • PHVS Netherlands
  • GHLD United States
  • Employees
  • PHVS N/A
  • GHLD N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • GHLD Finance: Consumer Services
  • Sector
  • PHVS Health Care
  • GHLD Finance
  • Exchange
  • PHVS Nasdaq
  • GHLD Nasdaq
  • Market Cap
  • PHVS 1.0B
  • GHLD 867.0M
  • IPO Year
  • PHVS 2021
  • GHLD 2020
  • Fundamental
  • Price
  • PHVS $18.54
  • GHLD $13.79
  • Analyst Decision
  • PHVS Strong Buy
  • GHLD Buy
  • Analyst Count
  • PHVS 5
  • GHLD 5
  • Target Price
  • PHVS $40.60
  • GHLD $16.30
  • AVG Volume (30 Days)
  • PHVS 66.5K
  • GHLD 10.7K
  • Earning Date
  • PHVS 11-13-2024
  • GHLD 11-06-2024
  • Dividend Yield
  • PHVS N/A
  • GHLD 3.61%
  • EPS Growth
  • PHVS N/A
  • GHLD N/A
  • EPS
  • PHVS N/A
  • GHLD N/A
  • Revenue
  • PHVS N/A
  • GHLD $829,864,000.00
  • Revenue This Year
  • PHVS N/A
  • GHLD $37.55
  • Revenue Next Year
  • PHVS N/A
  • GHLD $29.77
  • P/E Ratio
  • PHVS N/A
  • GHLD N/A
  • Revenue Growth
  • PHVS N/A
  • GHLD 4.51
  • 52 Week Low
  • PHVS $15.37
  • GHLD $12.78
  • 52 Week High
  • PHVS $33.00
  • GHLD $18.26
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 42.23
  • GHLD 48.89
  • Support Level
  • PHVS $18.18
  • GHLD $13.70
  • Resistance Level
  • PHVS $19.88
  • GHLD $14.42
  • Average True Range (ATR)
  • PHVS 1.17
  • GHLD 0.44
  • MACD
  • PHVS 0.08
  • GHLD 0.09
  • Stochastic Oscillator
  • PHVS 23.92
  • GHLD 41.22

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About GHLD Guild Holdings Company

Guild Holdings Co is a growth-oriented mortgage company. It operates in two segments; The origination segment operates its loan origination business throughout the United States. It is responsible for loan origination, acquisition, and sale activities. This segment is further divided into retail and correspondent channel, and The servicing segment provides a steady stream of cash flow to support the origination segment more importantly it allows for the Company to build long-standing client relationships that drive repeat and referral business back to the origination segment to recapture the client's next mortgage transaction. It is responsible for the servicing activities of all loans in its servicing portfolio. It generates a majority of its revenue from the Origination segment.

Share on Social Networks: